West Pharmaceutical CEO çıkış

West Pharmaceutical's Q3 2024 revenue guidance will be maintained or increased (no downward revision) despite CEO transition, with management affirming full-year 2024 outlook, demonstrating operational stability.

If West Pharmaceutical announces an internal successor within 60 days of CEO exit announcement, WST stock will recover and trade at or above pre-announcement levels by day 90, indicating market confidence in continuity.

West Pharmaceutical Services (WST) stock will experience a negative price reaction of 3-5% within 5 trading days following the CEO exit announcement due to succession uncertainty and potential disruption to strategic initiatives.